Belmac
This article was originally published in The Tan Sheet
Executive Summary
Forms joint venture agreement with New York-based health care firm Maximed to develop and introduce an extended-release vaginal contraceptive with nonoxynol-9 that will be self-administered with a biodegradable tubular applicator. Nonoxynol-9 will be incorporated into a "hydrogel-based delivery system" developed by Maximed. The firms expect to launch the product in the U.S. in early 1995